• Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:12012; TPM3; Name(s)=TPM3-ROS1 (DOI=10.1158/1538-7445.AM2020-3003; PubMed=36101520).
  

PubMed=29636358; DOI=10.1158/1078-0432.CCR-17-2452; PMCID=PMC6050099
McCoach C.E., Le A.T., Gowan K., Jones K.L., Schubert L., Doak A.E., Estrada-Bernal A., Davies K.D., Merrick D.T., Bunn P.A. Jr., Purcell W.T., Dziadziuszko R., Varella-Garcia M., Aisner D.L., Camidge D.R., Doebele R.C.
Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer.
Clin. Cancer Res. 24:3334-3347(2018)

DOI=10.1158/1538-7445.AM2020-3003
Tyler L.C., Le A.T., Nijmeh H., Doebele R.C.
MET mediates entrectinib resistance in ROS1 gene fusion positive NSCLC.
Cancer Res. 80 Suppl. 16:3003-3003(2020)

DOI=10.1158/1535-7163.TARG-21-P076
Tyler L.C., Le A.T., Nijmeh H., Bao L.-M., Turner K., Christianson J., Doebele R.C.
Novel mechanisms of acquired TKI resistance in ROS1+ NSCLC.
Mol. Cancer Ther. 20 Suppl. 12:P076-P076(2021)

PubMed=36101520; DOI=10.1111/1759-7714.14656; PMCID=PMC9626307
Tyler L.C., Le A.T., Chen N., Nijmeh H., Bao L.-M., Wilson T.R., Chen D., Simmons B., Turner K.M., Perusse D., Kasibhatla S., Christiansen J., Dudek A.Z., Doebele R.C.
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Thorac. Cancer 13:3032-3041(2022)

DOI=10.63028/10067/2105480151162165141
Terrones M.
Profiling targeted therapy responses in ROS1+ non-small cell lung cancer using genomically engineered patient-derived cell lines.
Thesis PhD (2024); University of Antwerp; Antwerp; Belgium